BENTLEY EXPANDS INTRANASAL INSULIN TRIALS TO INDIA

Bentley Pharmaceuticals announced it has received approval from the Drugs Controller General of India to proceed with a Phase II clinical trial of Nasulin in Type 2 diabetes.

Nasulin is the company's intranasal insulin product that uses its proprietary CPE-215 delivery technology.

The company recently completed pharmacokinetic studies of Nasulin in India. The 12-week Phase II study will begin in March and is expected to be completed before the end of the year. Data from the Indian study will supplement the Phase II trial currently under way in the U.S.

Biocon, India's largest insulin producer, is Bentley's licensing partner for developing and marketing Nasulin in India. "Biocon truly believes that non-injectable insulins will drive the future of diabetes therapy," Rakesh Bamzai, president of marketing at Biocon, said.